Public Health Innovation Biopharmaceuticals Lost in Translation?

Taking treatments from bench to bedside, or bench to community, requires a viable pathway connecting molecular science to global need through public and private research funding, clinical development, drug marketing, and policy making. In this paper, the authors present a systematic analysis of the...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic Innovation & Regulatory Science Vol. 47; no. 3; pp. 306 - 311
Main Authors Halim, Nader D., Doyle, John J.
Format Book Review Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 01.05.2013
Springer International Publishing
Springer Nature B.V
Subjects
Acquired immune deficiency syndrome
AIDS
Drug development
Drug Safety and Pharmacovigilance
Medical research
Pharmaceutical industry
Pharmacotherapy
Pharmacy
Public Health
Science
biopharmaceuticals
drug development
public health innovation
Online AccessGet full text

Cover

More Information
Summary:Taking treatments from bench to bedside, or bench to community, requires a viable pathway connecting molecular science to global need through public and private research funding, clinical development, drug marketing, and policy making. In this paper, the authors present a systematic analysis of the effectiveness of translating basic science into reduced global burden of disease as a proxy for systemic public health impact. They pose a compound research question: Is the current drug development pipeline aligned with current and future global burden of disease, and, if not, where do the disconnections occur?
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:2168-4790
2168-4804
DOI:10.1177/2168479013482315